Corbus Pharmaceuticals (CRBP) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Rani Therapeutics (RANI) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 60.9% versus a loss of 76.6%. Over five years, CRBP leads with a -84.2% price change compared with -96.5% for RANI. Rani Therapeutics is the larger company by market cap ($90.0 million vs $87.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | RANI |
|---|---|---|
| Share price | $4.52 | $0.6406 |
| Market cap | $87.42M | $90.02M |
| 1-day change | +4.39% | -5.79% |
| YTD return | -44.47% | -52.55% |
| 1-year return | -76.60% | -60.94% |
| 5-year return | -84.16% | -96.54% |
| EPS (TTM) | $-6.11 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.63M |
| Revenue growth (YoY) | — | +58.85% |
| Net income (latest FY) | $-78.54M | $-29.67M |
| Operating margin | — | -2345.99% |
| Net margin | — | -1817.09% |
| 52-week high | $20.56 | $3.87 |
| 52-week low | $4.22 | $0.613 |
| Distance from 52-week high | -78.02% | -83.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +652.88% | +1023.95% |
| Average volume | 825.10K | 720.45K |
| Shares outstanding | 19.34M | 115.42M |
| Employees | 36 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RANI has outperformed CRBP by 15.7 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
CRBP vs RANI FAQ
Which is bigger, Corbus Pharmaceuticals or Rani Therapeutics?
Rani Therapeutics (RANI) is larger, with a market capitalization of $90.02M compared with $87.42M for Corbus Pharmaceuticals (CRBP).
Which stock has performed better over the past year, CRBP or RANI?
RANI returned -60.94% over the past 12 months, compared with -76.60% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.